Ob-gyns respond to recent FDA discussion on SSRIs in pregnancy

Abstract

When the federal Food and Drug Administration (FDA) recently discussed the use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy, the result was confusion among many. For years, research has shown that risks to the fetus and newborn — and developing child — are minor, and that these risks are outweighed by benefits to the mother. The benefits are to the child as well, because of the risks of maternal depression on children. But the FDA panel specifically discussed the risks of SSRIs in pregnancy.